4.7 Article

DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway

期刊

CELL DEATH & DISEASE
卷 9, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41419-018-0591-0

关键词

-

资金

  1. Natural Science Foundation of Guangdong Province [2014A030313090, 2014A030313190]
  2. Science and Technology Projects Foundation of Guangdong Province [2015A070710006, 2016A020215053]
  3. Science and Technology Projects Foundation of Guangzhou City [201507020037, 201607010260]
  4. National Natural Science Foundation of China [81602701]

向作者/读者索取更多资源

Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide; however, the molecular mechanisms regulating HCC progression remain largely unknown. In this study, we determined the role of DDX39 which a DEAD-box RNA helicase in HCC progression, and found DDX39 was upregulated in HCC tissues and cells, DDX39 expression was positive correlated with advanced clinical stage, survival analysis showed patients with high-DDX39 levels had poor outcome, it was an independent prognostic factor. Functional analysis revealed that DDX39 overexpression promoted HCC cell migration, invasion, growth, and metastasis, DDX39 knockdown inhibited HCC cell migration, invasion, growth, and metastasis. Mechanism analysis suggested DDX39 overexpression increased beta-catenin expression in nucleus and increased Wnt/beta-catenin pathway target genes levels, while DDX39 knockdown reduced this effect. Knockdown of Wnt/beta-catenin pathway co-activators TCF4 and LEF1 in DDX39 overexpressing HCC cells inhibited Wnt/beta-catenin pathway target genes. The invasion ability was also reduced, confirming DDX39 regulates HCC progression by activating Wnt/beta-catenin pathway. In conclusion, we found DDX39 is a target and prognostic factor for HCC, and promotes HCC migration, invasion, growth, and metastasis by activating Wnt/beta-catenin pathway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据